Cudarolimab
Based on 1 Customer Validation
Cudarolimab (IBI101) is a completely human anti-OX40 (CD134, a co stimulating molecule expressed by activated immune cells) antibody. Cudarolimab inhibits the binding of OX40 to its ligand OX40L. Cudarolimab has antitumor activity and can be used in cancer related research.
For research use only. We do not sell to patients.
- Purity: 95.00%
- CAS No.: 2244739-29-3
- Molecular Weight:145.94 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All Orexin Receptor (OX Receptor) Isoforms
More
Biological Activity
Human IgG1 kappa
Human
TNFRSF4/OX40/CD134
Cudarolimab (0.01, 1, 100 or 10000 nM) binds to OX40 and partially blocks the binding of OX40 to its ligand OX40L in CHO-S cells overexpressing human OX40 (CHO-S-hOX40). Cudarolimab activates OX40 dependent NF-κB reporters with an EC50 value of 4.432 nM in Jurkat-OX40 reporter cells co-cultured with Raji cells[1].
Cudarolimab (0.01, 0.1, 1, 10, 100 or 1000 nM) binds to activated human CD4+ T cells and activated cynomolgus monkey CD4+ T cells in a dose dependent manner[1].
Cudarolimab (0.4, 4.0 and 40.4 nM) increases IL-2 secretion with dose dependent manner in human CD4+ T cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Cudarolimab (0.1, 1 and 10 mg/kg; i.p.; single dose on days 6, 9, 12 and 16) significantly reduces tumor volume, increases IFN-γ+ and IFN-α+ expression in CD8+ T cells in tumor and spleen of human OX40 knock-in mice bearing MC38 tumors[1].
Cudarolimab (10 mg/kg; i.p.; single dose on days 10 and 14) significantly reduces the expression of CD3+CD8+, CD3+CD4+, CD4+CD25highFoxP3+ in the tumor and spleen of human OX40 knock-in mice bearing MC38 tumors[1].
Pharmacokinetic (PK) parameters of Cudarolimab in cynomolgus macaques[1]
| Dose (mg/kg) | Cmax (µg/mL ) | Tmax (h) | AUC0-∞ (h•µg/mL ) | T1/2 (h) | Cl (mL/h/kg) | MRTlast (h) |
| 0.1 | 3.07±0.40 | 0.08±0.00 | 347.98±99.30 | 162.98±103.01 | 0.31±0.08 | 186.34±110.68 |
| 0.5 | 9.78±3.27 | 0.40±0.78 | 1429.19±607.21 | 129.47±114.44 | 0.40±0.14 | 136.03±108.05 |
| 2.5 | 63.10±15.29 | 0.08±0.00 | 10304.06±3403.59 | 190.89±92.94 | 0.27±0.09 | 212.29±114.61 |
| 12.5 | 296.57±58.05 | 0.40±0.78 | 33511.65±14982.36 | 120.30±153.26 | 0.44±0.20 | 114.93±87.66 |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Humanized NOG mice bearing LoVo tumors[1].
-
Dosage:10 mg/kg.
-
Administration:Intraperitoneal injection; single dose on days 3, 7, 11, 14 and 15.
-
Result:Reduced tumor volume.
-
Animal Model:Human OX40 knock-in mice bearing MC38 tumors[1].
-
Dosage:0.1, 1 and 10 mg/kg.
-
Administration:Intraperitoneal injection; single dose on days 6, 9, 10, 12, 14 and 16.
-
Result:Showed anti-tumor activity.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Flow cytometric analysis of 1X106 500 ng/mL anti-CD3 and 500 ng/mL ant-CD28 co-stimulated Jurkat cells(24h) with Cudarolimab (HY-P99836, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS No. 2244739-29-3
-
Appearance Liquid
-
Molecular Weight 145.94 kDa
-
Color Colorless to light yellow
-
SMILES
[Cudarolimab]
-
Synonyms
IBI101
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz